NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $17.15 -0.27 (-1.55%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PHAT alerts:Sign Up Key Stats Today's Range$16.77▼$17.4250-Day Range$12.81▼$19.5052-Week Range$6.07▼$19.71Volume689,646 shsAverage Volume816,852 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$22.50Consensus RatingModerate Buy Company OverviewPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks45th Percentile Overall ScorePHAT MarketRank™: Phathom Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 706th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($6.03) to ($4.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.47% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 1.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.47% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 1.97%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.31 News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Stock News HeadlinesNeedham Sticks to Their Hold Rating for Lexicon Pharmaceuticals (LXRX)October 31 at 12:27 PM | markets.businessinsider.comLow-Volume Bowel Prep Matches Standard for Inpatient ColonoscopyOctober 29 at 7:59 PM | msn.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…October 31, 2024 | Porter & Company (Ad)Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024October 28 at 8:00 AM | globenewswire.comPhathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual MeetingOctober 27, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)October 25, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)September 25, 2024 | prnewswire.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $9.13 on January 1st, 2024. Since then, PHAT stock has increased by 87.8% and is now trading at $17.15. View the best growth stocks for 2024 here. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($1.35) earnings per share for the quarter, beating the consensus estimate of ($1.39) by $0.04. The firm had revenue of $7.32 million for the quarter, compared to analysts' expectations of $5.65 million. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' top institutional shareholders include Creative Planning (0.06%), SG Americas Securities LLC (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and US Bancorp DE (0.01%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi and Asit Parikh. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/08/2024Today10/31/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+34.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-2,995.67% Return on EquityN/A Return on Assets-75.81% Debt Debt-to-Equity RatioN/A Current Ratio6.48 Quick Ratio6.44 Sales & Book Value Annual Sales$9.92 million Price / Sales100.77 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-13.20Miscellaneous Outstanding Shares59,594,000Free Float45,232,000Market Cap$999.39 million OptionableOptionable Beta0.71 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:PHAT) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.